SCHEMBL4776267

SCHEMBL4776267

COc1ccccc1N1CC2C(C1)C2NC(=O)O

nearest known ligand 0.50

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
DRD2 P14416 4/20 0.49
DRD3 P35462 4/20 0.49
MCOLN2 Q8IZK6 1/20 0.47
MCOLN1 Q9GZU1 1/20 0.47
DRD4 P21917 1/20 0.47
ALDH1A1 P00352 3/20 0.46
KMT2A Q03164 2/20 0.46
PKM P14618 1/20 0.46
MEN1 O00255 1/20 0.46
POLB P06746 1/20 0.46
HSD11B1 P28845 1/20 0.46
KDM4E B2RXH2 1/20 0.45
LMNA P02545 1/20 0.45
TSHR P16473 1/20 0.45
MAPK1 P28482 1/20 0.45
HTT P42858 1/20 0.45
MAPT P10636 1/20 0.45
HPGD P15428 1/20 0.45
HTR1A P08908 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29138516 0.81 DRD2 (0.49) DRD2DRD3DRD4ALDH1A1HSD11B1
SCHEMBL17376246 0.80 MCOLN2 (0.50) DRD2DRD3MCOLN2MCOLN1DRD4
SCHEMBL29138525 0.79 DRD2 (0.53) DRD2DRD3DRD4ALDH1A1KMT2A
SCHEMBL20140998 0.79 MCOLN2 (0.55) DRD2DRD3MCOLN2MCOLN1DRD4
SCHEMBL4896088 0.75 NOTUM (0.46) ALDH1A1KMT2AMEN1LMNATSHR
SCHEMBL29138547 0.75 DRD2 (0.56) DRD2DRD3ALDH1A1KMT2AMEN1
SCHEMBL34463006 0.73 DRD2 (0.58) DRD2DRD3DRD4ALDH1A1KMT2A
SCHEMBL34462822 0.72 DRD2 (0.56) DRD2DRD3ALDH1A1HSD11B1LMNA
SCHEMBL3904994 0.70 KMT2A (0.68) DRD2DRD3ALDH1A1KMT2APKM
SCHEMBL4778958 0.69 ADRA1D (0.48) DRD2DRD3DRD4ALDH1A1MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2008010061-A2 3-AZABICYCLO [3.1.0] HEXANE VANILLOID RECEPTOR LIGANDS, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND PROCESSES FOR THEIR PREPARATION GLENMARK PHARMACEUTICALS S.A. (US) 2008-01-24 WO disclosed